Vitrafy Life Sciences (ASX:VFY) Cash Payments: A$-19.66 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:VFY Vitrafy Life Sciences Ltd ASX:VFY
4 GF Score
Price A$3.87
! 2 Warning Signs
View Full Analysis

What is Vitrafy Life Sciences Cash Payments?

Vitrafy Life Sciences ASX:VFY -1.53% 4 Cash Payments is A$-19.66 Mil as of Jun. 2026. GuruFocus rates ASX:VFY with a GF Score™ of 4/100. The stock has 2 warning signs investors should review.

Vitrafy Life Sciences's Cash Payments for the six months ended in Jun. 2026 was A$-10.48 Mil.

Vitrafy Life Sciences's Cash Payments for the trailing twelve months (TTM) ended in Jun. 2026 was A$-19.66 Mil.

Vitrafy Life Sciences Cash Payments Historical Data

* Premium members only.

The historical data trend for Vitrafy Life Sciences's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrafy Life Sciences Cash Payments Chart

Vitrafy Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Cash Payments
-6.50 -6.79 -8.88 -14.08 -19.66

Vitrafy Life Sciences Semi-Annual Data
Jun22 Jun23 Jun24 Dec24 Jun25 Dec25 Jun26
Cash Payments Get a 7-Day Free Trial 0.00 -6.12 -7.96 -9.19 -10.48
ASX:VFY
4GF Score
Vitrafy Life Sciences Ltd ASX:VFY
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrafy Life Sciences Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-19.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Payments →
What does a Cash Payments of A$-19.66 Mil mean?
Vitrafy Life Sciences (ASX:VFY) has a Cash Payments of A$-19.66 Mil as of Jun. 2026. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Vitrafy Life Sciences and its competitors.
Is Vitrafy Life Sciences' Cash Payments too high?
Vitrafy Life Sciences' current Cash Payments is A$-19.66 Mil. Overall, Vitrafy Life Sciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' Cash Payments compare to MSFT and PLTR?
Vitrafy Life Sciences' Cash Payments of A$-19.66 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Payments for a Software company?
A good Cash Payments depends on the Software industry context. However, Cash Payments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Payments mean?
A high Cash Payments can signal that a stock is expensive relative to its fundamentals. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Vitrafy Life Sciences and its competitors. Vitrafy Life Sciences's current Cash Payments is A$-19.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current Cash Payments of A$-19.66 Mil. The current Cash Payments is A$-19.66 Mil. Vitrafy Life Sciences' overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Payments calculated?
Cash Payments is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current Cash Payments is A$-19.66 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitrafy Life Sciences Business Description

Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
4GF Score

Get the complete analysis for ASX:VFY

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$3.87
Price